Highlights:
-- Orphan Drug Designation granted by FDA for Ga68-Trivehexin (RAD 301)
-- Successful completion of pre-Investigational New Drug (IND) meeting with the FDA concerning F18-pivalate (RAD 101)
-- Supply agreement announced with TerThera for the provision of the isotope Terbium-161 (Tb-161)
-- Educational webinar hosted on Pivalate platform technology
Sydney, Australia – 31 July 2023 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to provide a summary of its activities for the quarter ended 30 June 2023.
For more information, download the attached PDF.
Download this document
